[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":29670000.0,"LeaseCost_2_Q2_USD":1077000.0,"LeaseCost_1_Q2_USD":570000.0,"InvestmentIncomeAmortizationOfDiscount_2_Q2_USD":69000.0,"HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0_Q2_USD":0.0,"HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_0_Q2_USD":26000.0,"HeldToMaturitySecurities_0_Q2_USD":15058000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_Q2_USD":-331000.0,"DeferredRevenueNoncurrent_0_Q2_USD":686000.0,"ConstructionContractCostProgressPaymentOffset_0_Q2_USD":27000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":147879000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":275600000.0,"AmortizationOfLeaseIncentives_2_Q2_USD":110000.0,"LiabilitiesFairValueDisclosure_0_Q2_USD":343000.0,"AmortizationOfFinancingCosts_2_Q2_USD":463000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q2_USD":7370000.0,"OtherLiabilitiesCurrent_0_Q2_USD":25572000.0,"ShortTermInvestments_0_Q2_USD":15058000.0,"HeldToMaturitySecuritiesFairValue_0_Q2_USD":15084000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":261767000.0,"OtherAssetsCurrent_0_Q2_USD":1536000.0,"IncreaseDecreaseInOtherCurrentLiabilities_2_Q2_USD":-23464000.0,"IncreaseDecreaseInOtherCurrentAssets_2_Q2_USD":-3211000.0,"TreasuryStockValue_0_Q2_USD":234000.0,"TreasuryStockShares_0_Q2_shares":41309.0,"LongTermNotesPayable_0_Q2_USD":0.0,"IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_Q2_USD":-728000.0,"LongTermDebtCurrent_0_Q2_USD":7200000.0,"IncreaseDecreaseInInterestPayableNet_2_Q2_USD":-110000.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":-76000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":19072000.0,"OtherGeneralAndAdministrativeExpense_2_Q2_USD":13789000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":10615000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":1913000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_Q2_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_Q2_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_Q2_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_Q2_pure":0.0034,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_Q2_pure":0.0054,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_Q2_pure":1.8691,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_Q2_pure":1.9105,"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0_Q2_USD":2264693000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":2455000.0,"RestrictedStockExpense_2_Q2_USD":14095000.0,"RestrictedStockExpense_1_Q2_USD":6975000.0,"RestrictedCashNoncurrent_0_Q2_USD":1255000.0,"RestrictedCashAndInvestments_0_Q2_USD":1300000.0,"RestrictedCash_0_Q2_USD":1255000.0,"OtherResearchAndDevelopmentExpense_2_Q2_USD":68939000.0,"OtherResearchAndDevelopmentExpense_1_Q2_USD":34896000.0,"OtherLongTermDebt_0_Q2_USD":30000000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":9141000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":9938000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1655000.0,"OperatingLeaseLiability_0_Q2_USD":11593000.0,"OperatingLeaseCost_2_Q2_USD":1077000.0,"OperatingLeaseCost_1_Q2_USD":570000.0,"NotesPayableFairValueDisclosure_0_Q2_USD":343000.0,"MoneyMarketFundsAtCarryingValue_0_Q2_USD":15458000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":7479000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":948000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":1889000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":1911000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":1796000.0,"OtherGeneralAndAdministrativeExpense_1_Q2_USD":8617000.0,"NotesPayable_0_Q2_USD":343000.0,"StockOptionPlanExpense_2_Q2_USD":4343000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":108926690.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":112353414.0,"Revenues_2_Q2_USD":76000.0,"Revenues_1_Q2_USD":38000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-805215000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":331000.0,"ProfitLoss_1_Q2_USD":-52884000.0,"ProfitLoss_2_Q2_USD":-104000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":113000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-105949000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":12655000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":241173000.0,"LiabilitiesCurrent_0_Q2_USD":67537000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":294621000.0,"Liabilities_0_Q2_USD":100394000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":28695000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":14434000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.95,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.47,"Depreciation_2_Q2_USD":64000.0,"CommonStockValue_0_Q2_USD":127000.0,"CommonStockSharesOutstanding_0_Q2_shares":126649205.0,"CommonStockSharesIssued_0_Q2_shares":126690514.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":260512000.0,"AssetsCurrent_0_Q2_USD":280938000.0,"Assets_0_Q2_USD":294621000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":10535748.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":10535748.0,"AdditionalPaidInCapital_0_Q2_USD":999549000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"IncreaseDecreaseInAccruedInterestReceivableNet_2_Q2_USD":-41000.0,"StockOptionPlanExpense_1_Q2_USD":395000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":165042000.0,"ProceedsFromWarrantExercises_2_Q2_USD":96000.0,"NonoperatingIncomeExpense_2_Q2_USD":-2910000.0,"NonoperatingIncomeExpense_1_Q2_USD":-2039000.0,"LongTermDebtNoncurrent_0_Q2_USD":22233000.0,"LongTermDebt_0_Q2_USD":29433000.0,"Goodwill_0_Q2_USD":799000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q2_USD":343000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":194227000.0,"DeferredCompensationLiabilityCurrent_0_Q2_USD":3440000.0,"OtherIncome_2_Q2_USD":519000.0,"OtherIncome_1_Q2_USD":189000.0,"Cash_0_Q2_USD":245054000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0_Q2_shares":147058.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensation_1_Q2_USD":7370000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":72471000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":36449000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OperatingIncomeLoss_2_Q2_USD":-101090000.0,"OperatingIncomeLoss_1_Q2_USD":-50845000.0,"OperatingExpenses_2_Q2_USD":101166000.0,"OperatingExpenses_1_Q2_USD":50883000.0,"NotesPayableCurrent_0_Q2_USD":343000.0,"InterestPaidNet_2_Q2_USD":1555000.0,"InterestExpense_2_Q2_USD":3429000.0,"InterestExpense_1_Q2_USD":2228000.0,"IncreaseDecreaseInOtherAccruedLiabilities_2_Q2_USD":-2436000.0,"ShareBasedCompensation_2_Q2_USD":18438000.0,"UnamortizedDebtIssuanceExpense_0_Q2_USD":1542000.0,"Ticker":"TGTX","CIK":"1001316","name":"TG THERAPEUTICS, INC.","OfficialName":"TG Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1036853809.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200810"}]